Cemiplimab联合化疗对比化疗一线治疗晚期NSCLC:EMPOWER-Lung 3第2部分5年结果
EMPOWER-Lung 3第2部分5年随访显示,cemiplimab联合化疗对比单纯化疗一线治疗无EGFR/ALK/ROS1异常的晚期NSCLC,中位OS为21.1 vs 12.9个月(HR=0.66,P=0.0002),5年OS率19.4% vs 8.8%,长期疗效持续且安全性一致。
要点
- 中位OS 21.1 vs 12.9个月,HR=0.66,5年OS率19.4% vs 8.8%。
- 中位PFS 8.2 vs 5.5个月,ORR 43.6% vs 22.1%,CR 6.4% vs 0%。
- 完成36周期cemiplimab者停药后3年OS率57.3%。
核心结论
- 5年随访显示cemiplimab联合化疗一线治疗晚期NSCLC较单纯化疗持续带来长期生存获益,安全性特征一致。
研究设计与样本
- 随机2:1对照III期试验,共466例既往未治疗、无EGFR/ALK/ROS1异常的晚期NSCLC患者。
- cemiplimab组312例接受cemiplimab 350 mg每3周(至多108周)联合4周期化疗,对照组154例接受安慰剂联合4周期化疗。
- 主要终点为总生存期(OS),次要终点包括无进展生存期(PFS)和客观缓解率(ORR)。
主要发现
- 中位随访60.9个月,中位OS为21.1个月 vs 12.9个月(HR=0.66,95%CI 0.53-0.83,P=0.0002)。
- 中位PFS为8.2个月 vs 5.5个月(HR=0.58,95%CI 0.47-0.72,P<0.0001)。
- ORR为43.6% vs 22.1%;完全缓解率6.4%(20/312)vs 0%(0/154)。
- 5年OS率为19.4% vs 8.8%;鳞癌和非鳞癌组织学均显示疗效。
- 完成36周期cemiplimab的22.8%(71/312)患者,治疗完成后3年(约随机后5年)OS率为57.3%。
关键数值与推荐
- 全研究人群中,≥3级治疗中出现的不良事件发生率:cemiplimab联合化疗组49.4%,单纯化疗组32.7%。
临床怎么用
- 支持cemiplimab联合化疗作为无EGFR/ALK/ROS1异常晚期NSCLC的一线治疗选择,长期随访验证其生存获益。
- 完成36周期cemiplimab治疗的患者停药后仍显示较高OS率,提示有限疗程免疫治疗的长期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: EMPOWER-Lung 3 part 2 trial demonstrated significant survival benefits with cemiplimab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced NSCLC without EGFR, ALK, or ROS1 aberrations. Here, we report 5-year follow-up outcomes. METHODS: Patients were randomized 2:1 to receive cemiplimab (350 mg every 3 wk for up to 108 wk) or placebo plus four cycles of chemotherapy. Primary end point was overall survival (OS); secondary end points included progression-free survival and objective response rate. RESULTS: This study randomized 466 patients to cemiplimab plus chemotherapy (n = 312) or chemotherapy alone (n = 154). After a median follow-up of 60.9 months, median OS was 21.1 months for cemiplimab plus chemotherapy versus 12.9 months for chemotherapy alone (hazard ratio = 0.66 [95% confidence interval: 0.53-0.83], p = 0.0002); median progression-free survival was 8.2 months versus 5.5 months (hazard ratio = 0.58 [95% confidence interval: 0.47-0.72], p < 0.0001); objective response rate was 43.6% versus 22.1%; and complete response was observed in 6.4% of patients (20/312) versus 0% (0/154), respectively. Five-year OS probability was 19.4% for cemiplimab plus chemotherapy versus 8.8% for chemotherapy alone. Efficacy was demonstrated in both squamous and nonsquamous histology. For 22.8% of patients (71/312) who completed 36 cycles of cemiplimab treatment, OS probability was 57.3% at 3 years after treatment completion (approximately 5 y after randomization). Among the total study population, incidence of treatment-emergent adverse events of grade 3 or higher was 49.4% with cemiplimab plus chemotherapy and 32.7% with chemotherapy alone. CONCLUSIONS: With 5-year follow-up, cemiplimab plus chemotherapy continues to demonstrate durable long-term efficacy benefits versus chemotherapy alone with consistent safety profile, as first-line therapy for advanced NSCLC.
引用
- Baramidze A, Makharadze T, Gogishvili M, et al. Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncol. 2026. PMID: 42297188. doi:10.1016/j.jtho.2026.103980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。